Form 10-Q Revance Therapeutics, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
William Blair Reviews Revance Therapeutic (RVNC) EPS
May 13, 2024 7:04 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on Revance Therapeutic (NASDAQ: RVNC).
The analyst comments "Revance announced first quarter 2024 DAXXIFY revenues of $22.1 million, approximating our estimate of $22.2 million and just shy of consensus of $23.5 million. While the first quarter is typically... More
